BIOGEN, GENENTECH AT ODDS OVER DRUG'S FATE

Genentech Inc. and Biogen Idec Inc. are embroiled in a dispute over the development of a second-generation version of their blockbuster drug Rituxan. Genentech of South San Francisco, Calif., plans to proceed with development of the compound as a treatment for rheumatoid arthritis and another inflammatory disorder.
The Boston Globe